![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Gabinete Berthier y Martínez H. Lundbeck A/S |
---|---|
Information provided by: | Gabinete Berthier y Martínez |
ClinicalTrials.gov Identifier: | NCT00640198 |
Condition | Intervention | Phase |
---|---|---|
Aphasia Stroke |
Drug: memantine Behavioral: constraint-induced language therapy (CIAT) Drug: placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. |
Enrollment: | 28 |
Study Start Date: | March 2005 |
Study Completion Date: | November 2007 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group 1 Memantine: Active Comparator
Patients included in this group will receive memantine alone followed by memantine combined with intensive speech-language therapy.
|
Drug: memantine
Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
Behavioral: constraint-induced language therapy (CIAT)
CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
Drug: memantine
Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
|
Group 2: Placebo Comparator
Patients included in this group will receive placebo alone followed by memantine combined with intensive speech-language therapy.
|
Behavioral: constraint-induced language therapy (CIAT)
CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
Drug: placebo
Placebo
|
Ages Eligible for Study: | 18 Years to 69 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Spain | |
Gabinete Berthier y Martínez and Centro de Investigaciones Médico-Sanitarias (CIMES) University of Malaga | |
Malaga, Spain, 29001 |
Principal Investigator: | Marcelo L. Berthier, M.D., Ph.D | Gabinete Berthier y Martínez and Centro de Investigaciones Médico-Sanitarias (CIMES), University of Malaga |
Study ID Numbers: | M-10830, Gabinete Berthier y Martínez., Lundbeck, Spain, S.A. |
Study First Received: | March 17, 2008 |
Last Updated: | March 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00640198 |
Health Authority: | Spain: Ministry of Health and Consumption |
Aphasia Memantine Constraint-induced language therapy Event-related potentials |
Excitatory Amino Acids Signs and Symptoms Speech Disorders Dopamine Cerebral Infarction Aphasia |
Stroke Memantine Neurologic Manifestations Language Disorders Neurobehavioral Manifestations Communication Disorders |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Antiparkinson Agents Excitatory Amino Acid Agents Dopamine Agents Central Nervous System Agents Pharmacologic Actions Excitatory Amino Acid Antagonists |